Immunome Inc. — Director's Dealing 2025

Dec 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2025-12-19

Reporting Person: SIEGALL CLAY B (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-19	Common Stock	P	7278	$20.48	Acquired	860525	Direct
2025-12-19	Common Stock	G	200000	—	Disposed	660525	Direct

Footnotes

F1: The weighted average purchase price for the transaction report was $20.48, and the range of prices were between $20.36 and $20.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2: The Reporting Person gifted the shares of the Issuer's common stock to the Clay B. Siegall 2025 Grantor Retained Annuity Trust, of which the Reporting Person's brother is the trustee and the Reporting Person's children are the beneficiaries. The Reporting Person does not have or share investment control over these shares.

F3: The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025 (the "Lock-Up Agreement"). The transferee has agreed to be bound by the terms of the Lock-Up Agreement.